Cargando…
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial
BACKGROUND: First- and second-generation smallpox vaccines are contraindicated in individuals infected with human immunodeficiency virus (HIV). A new smallpox vaccine is needed to protect this population in the context of biodefense preparedness. The focus of this study was to compare the safety and...
Autores principales: | Overton, Edgar Turner, Stapleton, Jack, Frank, Ian, Hassler, Shawn, Goepfert, Paul A, Barker, David, Wagner, Eva, von Krempelhuber, Alfred, Virgin, Garth, Weigl, Josef, Meyer, Thomas Peter, Müller, Jutta, Bädeker, Nicole, Grünert, Robert, Young, Philip, Rösch, Siegfried, Maclennan, Jane, Arndtz-Wiedemann, Nathaly, Chaplin, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567089/ https://www.ncbi.nlm.nih.gov/pubmed/26380340 http://dx.doi.org/10.1093/ofid/ofv040 |
Ejemplares similares
-
Cardiac Safety of Modified Vaccinia Ankara for Vaccination against Smallpox in a Young, Healthy Study Population
por: Zitzmann-Roth, Eva-Maria, et al.
Publicado: (2015) -
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
por: Greenberg, Richard N., et al.
Publicado: (2016) -
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
por: Ilchmann, Heiko, et al.
Publicado: (2022) -
Modified vaccinia Ankara–Bavarian Nordic vaccine against mpox in children
por: Turtle, Lance, et al.
Publicado: (2023) -
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial
Publicado: (2016)